Asthma is a chronic lung disease affecting millions worldwide. While classically
acknowledged to result from allergen-driven type 2 inflammatory responses leading to IgE …

Using a therapeutic strategy that is free from traditional diagnostic labels and based on the
identification of “treatable traits”(TTs), which are influential in clinical presentations in each …

A significant number of patients with asthma remain uncontrolled despite treatment with
inhaled corticosteroids (ICS) and long‐acting β2 adrenergic bronchodilators (LABA). The …

Background A number of single-inhaler triple therapies are being developed for asthma,
including the extrafine formulation of beclometasone dipropionate (BDP), formoterol …

A growing number of large clinical trials are demonstrating that long-acting muscarinic
agents (LAMAs) are useful in the presence of severe uncontrolled asthma despite the …

Asthma is a chronic obstructive lung disease characterized by recurrent episodes of
bronchoconstriction and wheezing. Conventional asthma treatment involves the …

Introduction Since long-acting muscarinic antagonists (LAMA) are only indicated as add-on
therapy in subjects with moderate-to-severe asthma, there are concerns whether LAMA …

Background Asthma is a major cause of morbidity in children, despite the availability of
various treatments. In adults, tiotropium—a long-acting muscarinic antagonist—as add-on …

Introduction The value of treating asthma with the triple regimen of inhaled corticosteroid
(ICS), long-acting β2-agonist (LABA), and long-acting muscarinic antagonist (LAMA) …

Objective: The optimal use of drug combinations for the management of asthma is providing
significant results. This has prompted Interasma (Global Asthma Association) to take a …